IL VIGABATRIN COME TERAPIA 'ADD-ON' NELLE EPILESSIE PARZIALI: STUDIO DI 12 CASI

We studied 12 patients (pts) 7 males and 5 females, as compassionate cases, with an age between 20 and 54 years (mean 32.2 ys), with a duration of epilepsy between 15 and 30 years (mean 20.7 ys) all with diagnosis of drug-resistant epilepsy. Pts were 9 with drug resistant partial epilepsy (simple and complex partial seizures) and 3 with multifocal partial epilepsy with non progressive brain damage. 3 pts were dropped from the study, 1 for heavy drowsiness and atassic disturbances affer only 15 days of treatment and 1 for no seizure frequency decrease and drowsiness. The pts still on Vigabatrin have been followed for a period between 5 and 15 months. Tolerance was good, with the most frequently reported unwanted effect being drowsiness. Plasma concentration of other drugs were reduced, significantly for PHT.